Telisotuzumab Vedotin, DOCETAXEL
M18-868
Phase 3 small_molecule active
Quick answer
Telisotuzumab Vedotin, DOCETAXEL for c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active